Scientists from Florida campus of TSRI have found that one of the most widely prescribed pain and anti-inflammation drugs slows the growth rate of a specific kind of cancer in animal models and suggests the medication could have the same effect on other types of tumors. The new study focused on the effects of celecoxib (Pfizer’s Celebrex®) which targets “cyclooxygenase-2” (COX-2). This enzyme is also critical in the creation of prostaglandins, compounds that act like hormones and play a role in promoting tumor growth. COX-2 expression is typically low in normal tissue, but high in multiple types of cancers.

COX-2, Gordian knot or Achilles heel? (A) Physiological processes with significant COX-2 involvement...







Recent Comments